Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NAS Clear all
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies

NCT02062151
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Acupuncture
Other
Lead sponsor
University of South Florida
Other
Eligibility
1 Day to 3 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

NCT01965704
View directory record Official record
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 22, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome

NCT03533985
View directory record Official record
Conditions
NAS
Interventions
Song of Kin, Gato box, Ocean disc, Contingent singing, Tonal Vocal holding, Muted shaker
Behavioral · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
28 Weeks and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
New Orleans, Louisiana • Hackensack, New Jersey • New Hyde Park, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 8:08 AM EDT
Terminated Phase 2 Interventional Results available

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02787304
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Coronado, California • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal (NAS) Ketamine for Cancer Pain

NCT03146806
View directory record Official record
Conditions
Cancer, Pain
Interventions
Intranasal ketamine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

NCT01671410
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
oral morphine, sublingual buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

NCT00521248
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
buprenorphine, Oral morphine solution
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 8:08 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Up to 4 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 22, 2026, 8:08 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

NCT03092011
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine Sulfate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
Up to 10 Days
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome

NCT03670160
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Phenobarbital, Clonidine
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
35 Weeks and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 22, 2026, 8:08 AM EDT
Completed No phase listed Observational

MOms in REcovery (MORE) Study: Defining Optimal Care

NCT04251208
View directory record Official record
Conditions
Opioid-Related Disorders, NAS, Substance Use Disorders
Interventions
Observational Study
Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
444 participants
Timeline
2019 – 2024
U.S. locations
10
States / cities
Augusta, Maine • Bangor, Maine • Keene, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Not applicable Interventional

Physiology and Therapeutic Management of Neonatal Abstinence Syndrome

NCT02768844
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Stochastic Vibrotactile Stimulation (SVS), Control
Device · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
1 Day to 1 Year
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Neonatal Abstinence Syndrome

NCT01723722
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone, Diluted Deodorized Tincture of Opium
Drug
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
1 Day to 6 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 22, 2026, 8:08 AM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Fetal and Infant Effects of Maternal Buprenorphine Treatment

NCT01561079
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jul 22, 2026, 8:08 AM EDT
Completed No phase listed Observational Results available

Donor Human Milk in Neonatal Abstinence Syndrome

NCT02182973
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
donor human milk
Dietary Supplement
Lead sponsor
Neolac Inc dba Medolac Laboratories
Industry
Eligibility
38 Weeks to 42 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Not applicable Interventional

RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure

NCT02334111
View directory record Official record
Conditions
Opioid Use Disorder, Neonatal Abstinence Syndrome, Child Development, Child Abuse, Child Neglect
Interventions
RESPECT-Plus
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
Up to 21 Days
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 22, 2026, 8:08 AM EDT
Terminated Not applicable Interventional Results available

Clonidine for Neonatal Abstinence Syndrome Study

NCT01175668
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Phenobarbital
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
Up to 15 Days
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome

NCT02801331
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Stochastic Vibrotactile Stimulation (SVS)
Device
Lead sponsor
Elisabeth B Salisbury
Other
Eligibility
1 Hour to 18 Months
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jul 22, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Maternal Buprenorphine-naloxone Treatment and the Infant

NCT03291847
View directory record Official record
Conditions
Maternal Opioid Use Disorder, Opioid Exposed Infant
Interventions
fetal monitoring, Buprenorphine Naloxone
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 22, 2026, 8:08 AM EDT